A randomized controlled trial of the effectiveness of Housing First in a small Canadian City.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
22 Aug 2019
Historique:
received: 13 01 2018
accepted: 14 08 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 27 11 2019
Statut: epublish

Résumé

The paper presents two-year findings from a study investigating the effectiveness of Housing First (HF) with assertive community treatment (ACT) in helping individuals with serious mental illness, who are homeless or precariously housed and living in a small city, to become stably housed. The research design was a parallel group non-blinded RCT with participants randomly assigned after the baseline interview to receive HF with ACT (N = 100) or treatment as usual (TAU; N = 101). Participants were interviewed every 3 months over 21/24 months to investigate changes on a range of housing and psychosocial outcomes. The primary outcomes were housing stability (as defined by a joint function of number of days housed and number of moves) and improvement in community functioning. Secondary predicted outcomes were improvements in self-rated physical and mental health status, substance use problems, quality of life, community integration, and recovery. An intent-to-treat analysis was conducted. Compared to TAU participants, HF participants who entered housing did so more quickly (23.30 versus 88.25 days, d = 1.02, 95% CI [0.50-1.53], p < 0.001), spent a greater proportion of time stably housed (Z = 5.30, p < 0.001, OR = 3.12, 95% CI [1.96-4.27]), and rated the quality of their housing more positively (Z = 4.59, p < 0.001, d = 0.43, 95% CI [0.25-0.62]). HF participants were also more likely to be housed continually in the final 6 months (i.e., 79.57% vs. 55.47%), χ The study indicates that HF ends homelessness significantly more rapidly than TAU for a majority of individuals with serious mental illness who have a history of homelessness and live in a small city. In addition, compared to TAU, HF produces psychosocial benefits for its recipients that include an enhanced quality of life, a greater sense of belonging in the community, and greater improvements in perceived recovery from mental illness. International Standard Randomized Control Trial Number Register Identifier: ISRCTN42520374 , assigned August 18, 2009.

Sections du résumé

BACKGROUND BACKGROUND
The paper presents two-year findings from a study investigating the effectiveness of Housing First (HF) with assertive community treatment (ACT) in helping individuals with serious mental illness, who are homeless or precariously housed and living in a small city, to become stably housed.
METHODS METHODS
The research design was a parallel group non-blinded RCT with participants randomly assigned after the baseline interview to receive HF with ACT (N = 100) or treatment as usual (TAU; N = 101). Participants were interviewed every 3 months over 21/24 months to investigate changes on a range of housing and psychosocial outcomes. The primary outcomes were housing stability (as defined by a joint function of number of days housed and number of moves) and improvement in community functioning. Secondary predicted outcomes were improvements in self-rated physical and mental health status, substance use problems, quality of life, community integration, and recovery.
RESULTS RESULTS
An intent-to-treat analysis was conducted. Compared to TAU participants, HF participants who entered housing did so more quickly (23.30 versus 88.25 days, d = 1.02, 95% CI [0.50-1.53], p < 0.001), spent a greater proportion of time stably housed (Z = 5.30, p < 0.001, OR = 3.12, 95% CI [1.96-4.27]), and rated the quality of their housing more positively (Z = 4.59, p < 0.001, d = 0.43, 95% CI [0.25-0.62]). HF participants were also more likely to be housed continually in the final 6 months (i.e., 79.57% vs. 55.47%), χ
CONCLUSIONS CONCLUSIONS
The study indicates that HF ends homelessness significantly more rapidly than TAU for a majority of individuals with serious mental illness who have a history of homelessness and live in a small city. In addition, compared to TAU, HF produces psychosocial benefits for its recipients that include an enhanced quality of life, a greater sense of belonging in the community, and greater improvements in perceived recovery from mental illness.
TRIAL REGISTRATION BACKGROUND
International Standard Randomized Control Trial Number Register Identifier: ISRCTN42520374 , assigned August 18, 2009.

Identifiants

pubmed: 31438912
doi: 10.1186/s12889-019-7492-8
pii: 10.1186/s12889-019-7492-8
pmc: PMC6704672
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1154

Références

Can J Commun Ment Health. 1996 Spring;15(1):5-20
pubmed: 10163559
Psychiatr Serv. 2000 Apr;51(4):487-93
pubmed: 10737824
Arch Gen Psychiatry. 2003 Sep;60(9):940-51
pubmed: 12963676
Schizophr Bull. 2004;30(4):1035-41
pubmed: 15957202
Health Econ. 2006 Nov;15(11):1229-36
pubmed: 16625671
Am J Addict. 2006;15 Suppl 1:80-91
pubmed: 17182423
J Nerv Ment Dis. 2007 Jan;195(1):83-8
pubmed: 17220745
Community Ment Health J. 2007 Jun;43(3):211-28
pubmed: 17401684
J Prim Prev. 2007 Jul;28(3-4):265-79
pubmed: 17592778
Addiction. 2008 Jan;103(1):42-52
pubmed: 17999707
Adm Policy Ment Health. 2008 Sep;35(5):370-8
pubmed: 18561020
PLoS Med. 2008 Dec 2;5(12):e225
pubmed: 19053169
Community Ment Health J. 2011 Apr;47(2):227-32
pubmed: 20063061
Arch Gen Psychiatry. 2010 Jun;67(6):645-52
pubmed: 20530014
Am J Community Psychol. 2012 Mar;49(1-2):142-55
pubmed: 21557093
BMJ Open. 2011 Nov 14;1(2):e000323
pubmed: 22102645
J Addict Dis. 2012;31(3):270-7
pubmed: 22873188
Soc Psychiatry Psychiatr Epidemiol. 2013 Aug;48(8):1245-59
pubmed: 23748928
PLoS One. 2013 Sep 04;8(9):e72946
pubmed: 24023796
Eval Program Plann. 2014 Apr;43:16-26
pubmed: 24246161
Psychiatr Serv. 2014 Mar 1;65(3):287-94
pubmed: 24343350
Soc Psychiatry Psychiatr Epidemiol. 2015 Feb;50(2):195-202
pubmed: 24917487
Psychiatr Serv. 2015 May 1;66(5):463-9
pubmed: 25639993
Am J Community Psychol. 2015 Jun;55(3-4):279-91
pubmed: 25772023
BMC Psychol. 2015 Aug 20;3:28
pubmed: 26289918
Psychiatr Serv. 2016 Mar;67(3):275-81
pubmed: 26620289
Can J Psychiatry. 2015 Nov;60(11):467-74
pubmed: 26720504
Am J Community Psychol. 2016 Sep;58(1-2):123-35
pubmed: 27473922
BMC Public Health. 2016 Oct 21;16(1):1110
pubmed: 27769226
CMAJ Open. 2017 Jul 18;5(3):E576-E585
pubmed: 28724726
Community Ment Health J. 1994 Oct;30(5):459-72
pubmed: 7851100
Soc Psychiatry Psychiatr Epidemiol. 1996 Mar;31(2):78-88
pubmed: 8881088
J Consult Clin Psychol. 1997 Jun;65(3):476-84
pubmed: 9170771
Am J Community Psychol. 1998 Apr;26(2):207-32
pubmed: 9693690
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538

Auteurs

Tim Aubry (T)

School of Psychology & Centre for Research on Educational and Community Services, University of Ottawa, Vanier Hall #5018, Ottawa, ON, K1N 6N5, Canada. taubry@uottawa.ca.

Jimmy Bourque (J)

Centre de recherche et de développement en éducation, Faculté des sciences de l'éducation, Université de Moncton, Moncton, NB, Canada.

Paula Goering (P)

Centre for Addiction and Mental Health & Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Susan Crouse (S)

Salvus Clinic, Moncton, NB, Canada.

Scott Veldhuizen (S)

Centre for Addictions and Mental Health, Toronto, ON, Canada.

Stefanie LeBlanc (S)

Centre de recherche et de développement en éducation, Faculté des sciences de l'éducation, Université de Moncton, Moncton, NB, Canada.

Rebecca Cherner (R)

School of Psychology & Centre for Research on Educational and Community Services, University of Ottawa, Vanier Hall #5018, Ottawa, ON, K1N 6N5, Canada.

Paul-Émile Bourque (PÉ)

École de psychologie, Université de Moncton, Moncton, ON, Canada.

Sarah Pakzad (S)

École de psychologie, Université de Moncton, Moncton, ON, Canada.

Claudette Bradshaw (C)

Mental Health Commission of Canada, Ottawa, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH